Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | GLA | P06280 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6228239 | 0.71 | ALDH1A1 (0.38) | KDM4ETRPA1ALDH1A1LMNAALOX5 | |
| SCHEMBL6228236 | 0.71 | ALDH1A1 (0.38) | KDM4ETRPA1ALDH1A1LMNAALOX5 | |
| SCHEMBL31492024 | 0.69 | ALDH1A1 (0.42) | KDM4EKMT2ATRPA1ALDH1A1LMNA | |
| SCHEMBL20439243 | 0.68 | ALDH1A1 (0.42) | KDM4ETRPA1ALDH1A1LMNAALOX5 | |
| SCHEMBL22092367 | 0.65 | CA12 (0.44) | KDM4EHTTL3MBTL1ALDH1A1LMNA | |
| SCHEMBL22092369 | 0.65 | CA12 (0.44) | KDM4EHTTL3MBTL1ALDH1A1LMNA | |
| SCHEMBL28048626 | 0.64 | CCNB2 (0.53) | KDM4ETRPA1ALDH1A1LMNAALOX5 | |
| SCHEMBL21355057 | 0.64 | KDM4E (0.42) | KDM4EGLAHTTKMT2ASMN1; SMN2 | |
| SCHEMBL32684974 | 0.64 | KDM4E (0.42) | KDM4EGLAHTTKMT2ASMN1; SMN2 | |
| SCHEMBL27579404 | 0.62 | MAPT (0.47) | KDM4EGLAHTTKMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2005121160-A2 | 11, 12 CYCLIC THIOCARBAMATE MACROLIDE ANTIBACTERIAL AGENTS | JOHNSON & JOHNSON PHARMACEUTICAL RESEARCH & DEVELOPMENT (US) | 2005-12-22 | — | — | WO | disclosed |
| US-20050250713-A1 | 11,12-Cyclic thiocarbamate macrolide antibacterial agents | ZHU BIN | 2005-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050250713-A1 | 11,12-Cyclic thiocarbamate macrolide antibacterial agents | MRPL21, TTC14, MRPL12 | KDM4E 3190/4885GLA 3172/4885HTT 3038/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.